Die Suchmaschine für Unternehmensdaten in Europa
UK-Förderung (580.335 £): Digitales Design von Arzneimitteln Ukri 01.06.2014 Forschung und Innovation im Vereinigten Königreich, Großbritannien
Auf einen Blick
Text
Digitales Design von Arzneimitteln
| Zusammenfassung | This project brings together experts in drug development, product formulation, process design, systems modelling and manufacture to create a completely new approach to the design and manufacture of formulated drug products, which involves the integration of qualitative tools for process understanding with a range of in-silico models which describe and predict processing and product performance. It is anticipated that successful outcomes of digital design of drug formulations as envisaged in this proposal via the creation of “Design Space Explorer” will provide unparalleled improvements in reliability, quality and manufacturing processes of pharmaceutical products leading to greater trust by regulatory agencies and by society. Furthermore it is anticipated that a successful outcome to the proposed project has potential to significantly decrease the costs and times associated with the development of new medicines whilst also reducing, refining and and at times removing the need for some clinical studies in patients and healthy volunteers. |
| Kategorie | Collaborative R&D |
| Referenz | 101720 |
| Status | Closed |
| Laufzeit von | 01.06.2014 |
| Laufzeit bis | 31.05.2016 |
| Fördersumme | 580.335,00 £ |
| Quelle | https://gtr.ukri.org/projects?ref=101720 |
Beteiligte Organisationen
| SIEMENS PROCESS SYSTEMS ENGINEERING LIMITED |
443.597,00 £ |
| GLAXOSMITHKLINE SERVICES UNLIMITED |
30.204,00 £ |
| BRITEST LIMITED |
75.298,00 £ |
| ASTRAZENECA UK LIMITED |
31.236,00 £ |
| PFIZER LIMITED |
Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Siemens Process Systems Engineering Ltd., Farnborough, Großbritannien.
